
Opinion|Videos|November 12, 2024
CHEST 2024: Updates in IPF and PAH Care
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management (particularly chronic cough), and developing more effective, accessible therapies to enhance long-term patient outcomes.
Advertisement
Episodes in this series

Now Playing
1. Coming into CHEST 2024, what would you consider to be the largest unmet needs in the treatment and management of IPF and PAH?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Shifts in Colorectal Cancer Screening Trends After COVID-19
2
3 New Study Findings to Look Out for at Menopause Society 2025
3
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-modulatory, Off-the-Shelf Cancer Vaccine
4
Medicare Programs Observe an Increase in Participating Physicians Despite Burnout
5